Grifols S.A. Cl B | Balance Sheet

Fiscal year is January-December. All values EUR Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
709
1,079
1,143
895
887
1,034
Total Accounts Receivable
463
608
477
529
385
402
Inventories
947
1,194
1,431
1,643
1,629
1,949
Other Current Assets
21
32
39
56
44
99
Total Current Assets
2,140
2,913
3,089
3,123
2,945
3,483
Net Property, Plant & Equipment
840
1,148
1,644
1,810
1,760
1,952
Total Investments and Advances
42
55
107
291
284
229
Long-Term Note Receivable
9
4
-
-
-
100
Intangible Assets
2,776
4,243
4,694
4,839
5,860
6,595
Other Assets
-
4
-
-
5
6
Total Assets
5,841
8,450
9,602
10,130
10,920
12,477
ST Debt & Current Portion LT Debt
248
163
186
203
133
Accounts Payable
274
440
410
461
423
Income Tax Payable
4
19
23
32
7
Other Current Liabilities
189
459
434
376
415
Total Current Liabilities
715
1,080
1,053
1,072
978
Long-Term Debt
2,438
4,072
4,572
4,681
5,878
Provision for Risks & Charges
4
7
5
5
6
Deferred Taxes
419
456
565
533
323
Other Liabilities
115
83
26
31
24
Total Liabilities
3,727
5,780
6,287
6,390
7,274
Common Equity (Total)
2,101
2,658
3,296
3,721
3,629
Total Shareholders' Equity
2,101
2,658
3,296
3,721
3,629
Total Equity
2,107
2,663
3,301
3,728
3,634
Liabilities & Shareholders' Equity
5,841
8,450
9,602
10,130
10,920
Accumulated Minority Interest
6
5
5
6
5
Non-Equity Reserves
7
7
13
12
12

About Grifols

View Profile
Address
Avinguda de la Generalitat, 152-158
Barcelona Catalonia 08174
Spain
Employees -
Website http://www.grifols.com
Updated 07/08/2019
Grifols SA is a vertically integrated global producer of plasma derivatives. Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers. The company operates through the following segments: Bioscience, Hospital, Diagnostic and Raw Materials.